Anti-virus agent and method for treatment of viral infection
A method of treatment of viral infection in a subject comprising administering to the subject a copolymer comprising an acrolein derived segment or a polyacrolein oligomer segment and a polyalkylene glycol oligomer segment, the copolymer having a molecular weight of no more than 1500 Daltons.
1. A method of treatment of a parenteral viral infection in a subject comprising systemically administering to the subject a copolymer comprising an acrolein-derived segment and a polyalkylene glycol oligomer segment, the copolymer having a molecular weight of no more than 1000 Daltons, wherein the copolymer is administered by a route selected from the group consisting of: oral administration, inhalation, transdermal delivery, injection and infusion.
2. The method according to claim 1 , wherein the acrolein-derived segment is a polyacrolein oligomer comprising two or more acrolein residues.
3. The method according to claim 1 , wherein the copolymer has a molecular weight of from 300 to 1000 Daltons.
4. The method according to claim 1 , wherein the polyalkylene glycol oligomer segment has a molecular weight in the range of from 200 to 600 Daltons.
5. The method according to claim 1 , wherein the polyalkylene glycol oligomer segment has a molecular weight in the range of from 200 to 400 Daltons.
6. The method according to claim 1 , wherein a polyalkylene glycol of the polyalkylene glycol oligomer segment is polyethylene glycol.
7. The method according to claim 1 , wherein the copolymer is administered by oral administration.
8. The method according to claim 1 , wherein the copolymer is administered by intravenous injection or infusion.
9. The method according to claim 1 , wherein the copolymer is administered as an aqueous solution comprising a copolymer concentration in the range of from 0.01% by weight to 20% by weight of the aqueous solution.
10. The method according to claim 1 , wherein the copolymer is administered orally in the form of a tablet, caplet, syrup or liquid.
11. The method according to claim 1 , wherein the copolymer is administered systemically at a dose in the range of from 1 mg to 1000 mg per kilogram of bodyweight per day.
12. The method according to claim 1 , wherein the parenteral viral infection is selected from the group consisting of a influenza viral infection, an HIV infection, a hepatitis viral infection, a Ross River viral infection, and a herpes viral infection.
13. The method according to claim 1 , wherein the parenteral viral infection is an influenza viral infection.